Incyte Corporation: Primary Myelofibrosis trials

The registry lists 22 Primary Myelofibrosis studies with Incyte Corporation as lead sponsor. 3 are open to participants now and 13 have results posted.

Phase 1 10Phase 2 11Phase 3 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of INCA036978 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07441694Phase 1
• A Study to Evaluate INCA035784 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07008118Phase 1
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsRecruitingNCT06034002Phase 1
• To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)CompletedNCT04629508Phase 2Results posted
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)TerminatedNCT04551066Phase 3Results posted
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)TerminatedNCT04551053Phase 3Results posted
• A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With MyelofibrosisCompletedNCT03144687Phase 2Results posted
• A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisTerminatedNCT02718300Phase 2Results posted
• An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesTerminatedNCT02712905Phase 1/2Results posted
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedNCT02711137Phase 1/2Results posted
• Alternative Dosing Strategy of Ruxolitinib in Patients With MyelofibrosisCompletedNCT01445769Phase 2Results posted
• Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)CompletedNCT01348490Phase 2Results posted
• Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis PatientsCompletedNCT01340651Phase 2Results posted
• Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)CompletedNCT01317875Phase 1Results posted
• COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialCompletedNCT00952289Phase 3Results posted
• Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisCompletedNCT00509899Phase 1/2Results posted
• A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT06313593Phase 1
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT05936359Phase 1
• A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibTerminatedNCT04640025Phase 2
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsActive, not recruitingNCT04279847Phase 1
• Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)CompletedNCT02953704
• An Open Label Study of Itacitinib Administered Orally in Patients With MyelofibrosisCompletedNCT01633372Phase 2